Under the conditions of the agreement,Amgenwill contribute cancer targets, and Kite will leverage its proprietary CAR system, research and advancement and manufacturing features, and knowledge. Kite will lead to conducting all preclinical study and cell making and digesting through Investigational New Medication filing. Each company will then lead to clinical development and commercialization of their particular CAR therapeutic candidates, including all related expenses. Kite will receive fromAmgenan upfront payment of$60 million, and also funding for R&D costs through IND submitting. Kite will be eligible to receive up to$525 millionin milestone payments perAmgenprogram based on the successful completion of regulatory and commercialization milestones, plus tiered high single – to double-digit royalties for sales and the permit of Kite's intellectual house for CAR T cell products.Amgenis eligible to receive up to$525 millionin milestone payments per Kite program, as well as tiered single-digit product sales royalties.Representatives from Abaxis and Antech Diagnostics will continue to work together, together with our distribution companions, to market a complete diagnostic remedy comprising Abaxis point-of-care diagnostic products and Antech Diagnostic's reference lab services. Related StoriesPoint-of-treatment diagnostics for EbolaMelatonin and the circadian rhythm: an interview with Professor Kennaway, University of AdelaideDiabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of PolyphotonixClint Severson, Chairman, President and CEO of Abaxis, said, AVRL was an exciting venture for Abaxis, and we are pleased that the opportunity was had by us to enter the reference laboratory market. We are pleased with our accomplishments with AVRL, and we thank the countless loyal customers that used our services.